In short: Cited as evidence, not a stance: less body weight means less pressure on the knee, "so you might not need" a Stryker knee replacement. GLP-1s are a second-order drag on orthopedic devices.
27:24my probability of getting heart disease, of becoming disabled, of having hip pain. We saw this with the Medtronics of the world. — Mhm. — And the Stryker, you get a Stryker kneecap replacement, that type of thing. Well, your knee doesn't have as much pressure on it and so you might not need that medical device.
In short: Excluded by Terranova's one healthcare rule. "The industry that's interesting in healthcare that over the last several years we always talked about on this show is medical devices, and they are trading awful. They don't have the revenue growth. It's Stryker, it's your Baxter, it's Intuitive Surgical, they're not giving you that revenue growth." He owns 15 healthcare names in the JOET ETF and only three lack double-digit revenue growth — the devices complex is where he will not go.
Stryker makes surgical implants and medical equipment. Terranova excludes it, and the whole medical-device group, for one reason he applies mechanically: the revenue is not growing fast enough.
His rule for healthcare in this market is that a company must deliver double-digit revenue growth — of the fifteen healthcare names in his ETF, only three fall short. Devices, in his words, "are trading awful" precisely because they do not clear that bar. It is worth noticing that this is a screen, not a judgement about the businesses; a device maker could be excellent and still fail the test.
In short: Sethi bought Stryker (funding it by selling Zimmer): the higher-quality name — "much better management, team leader, robotics" — and he's using its current cyber issue as the entry point into a high-quality company.
Stryker makes medical devices and is a leader in surgical robotics. Sarat Sethi bought it — funding the purchase by selling rival Zimmer Biomet — because he sees Stryker as the higher-quality company with much better management. He's using a current cybersecurity problem at Stryker as the dip to buy into a business he rates highly.
In short: Referenced as a dominant, high-touch medtech franchise sharing the post-COVID growth-moderation / multiple-compression dynamic. Not owned.
31:24Stryker, GE Healthcare, each company is so dominant in its
31:31high-touch device or service that it sells to hospitals and doctors. I think part of what happened is that you
In short: Still owns; thesis intact — aging population needs more knee/hip/spine procedures, products get patients out of hospital faster, and surgeon switching costs are high. Weakness = analysts over-modeled the post-COVID backlog + a cyber attack.
Stryker makes medical devices — knee, hip and spine implants and surgical tools. The stock dipped because analysts had over-estimated how much pent-up surgery demand would persist after COVID, and the company had a cyber attack.
Harris still owns it and likes the long-term story: an aging population needs more of these procedures, the devices get patients out of the hospital faster (which saves money), and surgeons rarely switch suppliers — the sales reps are literally in the operating room. A durable, sticky business catching a temporary dip.
42:02It's not that bad. It's down 14% from when you picked it. Um depending on the point though when people got in it's down a lot more. Medtech um a lot of high-profile misses and Striker is one of them. Yeah. Talk to me about why Striker has stumbled and what you think about it now. So I I I mean so I like Striker still.
In short: BEST BUY #5. "Stryker manufactures and sells surgical equipment, neurovascular products, and orthopedic implants (like artificial hips and knees) to hospitals worldwide", with "the aging global population" as "a massive tailwind". The mechanism is the Mako Robotic-Arm Assisted Surgery system on "a brilliant razor-and-blade model": "Once a hospital invests over a million dollars in a Mako robot and trains its surgeons to use it, they rarely switch"; and "Stryker doesn't just make money selling the robot, they make recurring revenue on the software, service contracts, and the specialized consumables required for every single surgery." Summed up as "a proven compounding machine that grows both organically and through acquisitions."
Stryker makes surgical equipment and orthopaedic implants — artificial hips and knees — sold to hospitals worldwide. An ageing population means steadily more of those operations, which is the simple tailwind behind the case.
The more interesting part is the Mako surgical robot, which works like razors and blades. A hospital spends over a million dollars on the robot and then trains its surgeons on it. Having done that, it almost never changes supplier — the cost and disruption are too great.
And the robot is not really where the money is. Every operation performed on it requires Stryker's own specialised disposable parts, plus software and service contracts. So the one-off sale creates a stream of repeat revenue that lasts as long as the machine does.
Ranked fifth of the month's five ideas.
In short: A razor-and-blade medical device business across orthopaedic implants, neurotechnology and surgical equipment: place the equipment, then earn on disposables, implants and service. The moat is training — "surgeons learn on Stryker tools during their training and stick with them for their careers", and switching means retraining, lower theatre efficiency and higher patient risk. Robotics: a three-year head start with the Mako surgical robot, with Q3 2025 its best quarter ever for new installations. Grown faster than its market for ten consecutive years at ~10% revenue growth, defended by 5,800 patents. Price: was over 50x, now "still over 30x trailing earnings. Expensive, but starting to get more reasonable"; target 20x forward = ~$283 against $327.
Stryker makes medical equipment: hip and knee implants, brain-surgery tools, hospital beds and surgical instruments. It sells the equipment once and then earns steadily from the implants, disposables and servicing that follow — the razor-and-blades pattern.
Its strongest protection is how surgeons are trained. A surgeon learns on particular instruments during training and generally uses that brand for a whole career; switching means retraining, working more slowly, and accepting more risk for the patient. That is a moat that renews itself with every new cohort of doctors.
It also got a three-year head start installing its Mako surgical robot in hospitals for knee and hip replacements, and once a hospital has one, the follow-on consumables come with it. Q3 2025 was its best quarter ever for new installations. It has grown faster than its market for ten years running, at about 10% a year, protected by 5,800 patents.
The shares used to cost over 50 times earnings and now cost just over 30 — cheaper, but still not cheap. The stated buying level is 20 times forward earnings, roughly $283 against $327.
In short: Terry Smith's largest disclosed position. Named to illustrate that Fundsmith's "simple, but beautiful" strategy is being applied to unimpeachable businesses and still underperforming — the point of the section is the factor, not the stock. No Compounding Quality view offered here.
In short: #8. Medical equipment, instruments and implants — hips and knees, endoscopy, operating-room equipment, spinal devices; a top-three player in reconstructive orthopaedic implants and the leader in OR equipment. "Stryker will benefit from our ageing population… hospitals are very loyal clients."
Stryker makes the hardware of surgery: replacement hips and knees, spinal implants, endoscopy cameras, operating-room equipment and hospital beds. It is one of the three biggest players in joint replacement and the leader in operating-room equipment.
Two things make it a coffee-can candidate for Slegers. Demand grows with the age of the population — older bodies need more joints replaced — and the customer is unusually sticky: surgeons are trained on a particular system and hospitals standardise around it, so switching means retraining staff and rebuying instruments.
Nothing matches this filter.
Verbatim excerpts from the public transcripts (auto-pulled at each mention's timestamp, lightly cleaned). Timestamps link into the video; "source page" opens that commentator's full analysis at this row. Click a mention's header line to expand it (one open at a time). For personal study — not investment advice.